00:51 , Jan 31, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Antibodies targeting CDCP1 and other extracellular antigens up-regulated by Ras could be used to deliver cytotoxic drug payloads to Ras-mutant cancers. Comparative mass spectrometry-based analysis of human epithelial cell lines expressing the oncogenic...
23:47 , Jan 25, 2018 |  BC Extra  |  Preclinical News

Targeting RAS via surface proteins

In a paper published in eLife, researchers at the University of California San Francisco identified a new way to target Ras-mutant tumors via up-regulated extracellular antigens. The team showed antibodies against one of the antigens...
18:03 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Mouse studies suggest inhibiting CDCP1 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, knockout of CDCP1 decreased inflammation and CD4+ T cell infiltration in the spinal...
18:42 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting CDCP1 could help treat metastatic triple-negative breast cancer (TNBC). In three human TNBC cell lines, CDCP1 knockdown increased numbers of cytoplasmic lipid droplets -- which decreased...
23:39 , Aug 2, 2017 |  BC Extra  |  Preclinical News

CDCP1 identified as potential autoimmune target

In a paper published in Proceedings of the National Academy of Sciences, researchers linked CUB domain containing protein 1 (CDCP1; CD318) to inflammatory arthritis and showed that knockout of the protein protected mice from autoimmune...
07:00 , May 28, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CUB domain containing protein 1 (CDCP1); epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)

Cancer INDICATION: Breast cancer Cell culture, mouse and patient sample studies suggest inhibiting CDCP1 could help treat Herceptin trastuzumab-resistant breast cancer. In HER2-positive primary and metastastic breast tumors from patients, levels of CDCP1 correlated with poor prognosis...
07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer ADAM9; CUB domain containing protein 1 (CDCP1) Studies in patient samples and mice suggest inhibiting...